Sichuan Kelun Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Sichuan Kelun Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 11.4% bzw. 8.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.5% betragen.

Wichtige Informationen

11.4%

Wachstumsrate der Gewinne

11.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.0%
Wachstumsrate der Einnahmen	8.6%
Zukünftige Eigenkapitalrendite	14.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors

Nov 17

Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet

Oct 28

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement

Sep 22

Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Aug 16

Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Jul 12

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

Jun 11

An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

May 21

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

May 02

If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Mar 19

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Mar 04

These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Feb 27

Gewinn- und Umsatzwachstumsprognosen

SZSE:002422 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	27,241	3,799	-1,022	5,207	8
12/31/2025	24,545	3,380	-1,963	4,577	9
12/31/2024	22,846	3,010	-1,838	4,270	9
9/30/2024	22,500	2,964	2,412	4,360	N/A
6/30/2024	22,482	2,852	2,454	4,454	N/A
3/31/2024	22,035	2,668	3,128	5,109	N/A
12/31/2023	21,454	2,456	3,568	5,337	N/A
9/30/2023	20,841	2,263	4,173	5,439	N/A
6/30/2023	20,712	2,241	4,273	5,264	N/A
3/31/2023	20,194	2,228	3,693	4,591	N/A
1/1/2023	19,038	1,705	2,230	3,127	N/A
9/30/2022	18,531	1,660	1,816	2,726	N/A
6/30/2022	18,170	1,478	2,185	3,208	N/A
3/31/2022	17,608	1,218	1,989	2,982	N/A
1/1/2022	17,277	1,103	1,857	2,847	N/A
9/30/2021	17,487	1,176	1,915	3,034	N/A
6/30/2021	17,465	1,119	1,098	2,247	N/A
3/31/2021	17,078	983	1,032	2,277	N/A
12/31/2020	16,464	829	988	2,219	N/A
9/30/2020	16,342	525	80	1,361	N/A
6/30/2020	15,945	412	297	1,608	N/A
3/31/2020	16,886	624	234	1,524	N/A
12/31/2019	17,636	938	886	2,217	N/A
9/30/2019	17,078	1,104	1,573	3,156	N/A
6/30/2019	17,482	1,167	2,065	3,344	N/A
3/31/2019	16,708	1,165	1,430	2,757	N/A
12/31/2018	16,352	1,213	1,624	2,954	N/A
9/30/2018	15,757	1,384	1,223	2,258	N/A
6/30/2018	14,285	1,265	N/A	1,608	N/A
3/31/2018	12,933	938	N/A	1,736	N/A
12/31/2017	11,435	748	N/A	1,203	N/A
9/30/2017	10,223	434	N/A	1,081	N/A
6/30/2017	9,412	455	N/A	1,493	N/A
3/31/2017	8,996	569	N/A	1,398	N/A
12/31/2016	8,566	585	N/A	1,725	N/A
9/30/2016	8,198	632	N/A	1,590	N/A
6/30/2016	8,024	622	N/A	1,525	N/A
3/31/2016	7,875	648	N/A	1,712	N/A
12/31/2015	7,763	645	N/A	1,239	N/A
9/30/2015	7,856	727	N/A	1,345	N/A
6/30/2015	7,892	874	N/A	1,237	N/A
3/31/2015	7,976	980	N/A	1,205	N/A
12/31/2014	8,023	1,002	N/A	1,219	N/A
9/30/2014	7,888	1,057	N/A	1,242	N/A
6/30/2014	7,617	1,082	N/A	1,226	N/A
3/31/2014	7,310	1,101	N/A	1,080	N/A
12/31/2013	6,831	1,080	N/A	1,050	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 002422Das prognostizierte Gewinnwachstum (11.4% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 002422Die Erträge des Unternehmens (11.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 002422Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 002422Die Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 002422Die Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 002422Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.5%).

Sichuan Kelun Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 10% to CN¥35.67

Price target increased by 10% to CN¥32.33

Price target increased by 14% to CN¥29.33

Price target increased to CN¥23.70

Consensus forecasts updated

Price target increased to CN¥22.03

Recent updates

Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet

Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2024 Interim Profit Distribution Plan to Be Implemented (A Shares), Payable on 23 October 2024

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 22%

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for the First Half of 2024

Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Sichuan Kelun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

Sichuan Kelun Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings released: EPS: CN¥1.69 (vs CN¥1.22 in FY 2022)

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Investor sentiment improves as stock rises 15%

Sichuan Kelun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 10% to CN¥35.67

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to CN¥32.33

Price target increased by 14% to CN¥29.33

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Cash Dividend on Share A for 2022, Payable on May 15, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Price target increased to CN¥23.70

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

High number of new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to CN¥22.03

Price target increased to CN¥23.50

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Final Distribution for the Year 2021, Payable on 16 May 2022

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS misses analyst expectations

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) announces an Equity Buyback for CNY 200 million worth of its shares.

High number of new directors

Sichuan Kelun Pharmaceutical Co., Ltd., Annual General Meeting, May 05, 2022

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.10 in 2Q 2020)

Price target decreased to CN¥22.47

Sichuan Kelun Pharmaceutical Co., Ltd. announced that it expects to receive CNY 3 billion in funding

Consensus EPS estimates fall to CN¥0.72

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥0.58 (vs CN¥0.66 in FY 2019)

Investor sentiment improved over the past week

New 90-day high: CN¥21.88

Analysts lower EPS estimates to CN¥0.56

New 90-day low: CN¥18.06

Price target lowered to CN¥25.97

New 90-day low: CN¥20.47

New 90-day low: CN¥21.62

Earnings beat expectations, revenue disappoints

Third quarter earnings released

Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun) entered into an agreement to acquire Shanghai Century Acquisition Corporation (Amex: SHA) in a reverse merger transaction.

First half earnings released